invoX Pharma completes acquisition of F-star Therapeutics for $161m
F-star is being acquired for a total cash consideration of approximately $161m or $7.12 per share. Currently, F-star is undertaking Phase II trials in Europe and the US.
Armada Acquisition has entered a definitive business combination agreement with Brains Bioceutical that values the latter at an implied pre-money equity value of about $750m.